Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

276
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
276
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

979
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
979
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

657
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
657
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

31
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

30
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
30
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

847
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
847

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol.

The Journal of clinical endocrinology and metabolism·2022
Same author

Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar.

Journal of the American College of Cardiology·2020
Same author

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.

Arteriosclerosis, thrombosis, and vascular biology·2018
Same author

Statins - Good drugs, not so good reputation.

International journal of cardiology·2018
Same author

Now is good, earlier is better.

European heart journal. Quality of care & clinical outcomes·2017
Same author

The nocebo effect in the context of statin intolerance.

Journal of clinical lipidology·2016
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Sep 1, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K

LDL Cholesterol-How Low Can We Go?

Jonathan A Tobert1

  • 1Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford OX3 7LF, UK.

Endocrinology and Metabolism Clinics of North America
|August 13, 2022
PubMed
Summary
This summary is machine-generated.

Lowering low-density lipoprotein (LDL) cholesterol to very low levels is safe and reduces cardiovascular events. However, reducing LDL cholesterol below 25 mg/dL offers minimal additional benefits.

Keywords:
Cardiovascular risk reductionGuidelinesHypocholesterolemiaLDL cholesterolSafety

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K

Related Experiment Videos

Last Updated: Sep 1, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Lipid-lowering agents effectively reduce LDL cholesterol.
  • Achieving LDL cholesterol levels around 40 mg/dL is associated with reduced atherosclerotic events.
  • Minimal adverse effects are observed with intensive LDL cholesterol lowering.

Purpose of the Study:

  • To determine if there is a threshold for LDL cholesterol lowering below which it becomes harmful.
  • To evaluate the potential for new adverse effects with further LDL cholesterol reduction.
  • To assess the point at which further LDL cholesterol lowering yields diminishing returns.

Main Methods:

  • Review of randomized controlled trials on lipid-lowering therapies.
  • Examination of evidence regarding safety and efficacy of very low LDL cholesterol levels.
  • Analysis of the relationship between LDL cholesterol concentration and clinical outcomes.

Main Results:

  • No known threshold identified below which lowering LDL cholesterol is harmful.
  • Evidence suggests minimal to no additional benefit from reducing LDL cholesterol below 25 mg/dL.
  • Intensive LDL cholesterol lowering to approximately 40 mg/dL is safe and effective.

Conclusions:

  • Further reduction of LDL cholesterol below 25 mg/dL is unlikely to provide significant clinical benefit.
  • Current evidence does not support a harmful threshold for LDL cholesterol reduction.
  • The focus remains on achieving optimal LDL cholesterol levels for cardiovascular risk reduction.